USP Comment Letter: Submitted to FDA on Cannabis in Clinical Research Draft Guidance (2020)

Submitted on September 17, 2020 - USP Comment Letter to FDA on Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research” Draft Guidance for Industry. Docket No. FDA-2020-D-1079